Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Joanita Ocen"'
Publikováno v:
Medicine. 51:28-31
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a414f05c0330eacc4377daecd958018
https://doi.org/10.1016/j.mpmed.2022.10.017
https://doi.org/10.1016/j.mpmed.2022.10.017
Autor:
Rob Jones, Joanita Ocen
Publikováno v:
Medicine. 48:97-102
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9dc3d16b52af71b8ec4f25c39695d0d
https://doi.org/10.1016/j.mpmed.2019.11.006
https://doi.org/10.1016/j.mpmed.2019.11.006
Autor:
Joanita Ocen, Satish Kumar
Publikováno v:
Medicine. 48:108-112
Non-cytotoxic systemic treatments are a major component of systemic anti-cancer treatment. Targeted therapies are used to treat multiple tumour sites in both potentially curative and palliative settings and can be used in combination with chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3147a8cd0f9f7d78017a6dc655bd90b5
https://doi.org/10.1016/j.mpmed.2019.11.008
https://doi.org/10.1016/j.mpmed.2019.11.008
Publikováno v:
Neuro-oncology Advances
Background Melanoma brain metastases (MBMs) have historically poor overall survival (OS). Recently introduced systemic anticancer therapies (SACTs), namely targeted therapies such as BRAF inhibitors and immunotherapy, to control advanced disease have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83fc0f5ea0c1274f692b9378ad5ede04
https://pubmed.ncbi.nlm.nih.gov/33392503
https://pubmed.ncbi.nlm.nih.gov/33392503
Publikováno v:
Neuro Oncol
The incidence of malignant melanoma (MM) is increasing in the UK; it’s projected to rise by 7% by 2035. MM has high predisposition to developing brain metastases (BM) with 50–60% of patients being affected. Stereotactic radiosurgery (SRS) and sur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37cd719f6c74d605c537f966457c693b
https://europepmc.org/articles/PMC6789689/
https://europepmc.org/articles/PMC6789689/
Autor:
Geisler, Reed S, Williams, Edward H, Beh, Ian, Bertelli, Gian Lippo, Gianfilippo Bertelli, Cathomas, Richard, Dooley, Michael, Earl, Helena M, Fehr, Martin, Giglio, Daniel, Lewis, Paul D, Pat-Rick Mark, Joanita Ocen, Poole, Susan G, Shepherd, Scott, Quinton, Amy, Weaver, Jamie, White, Je D, Jodrell, Duncan I, Tavaré, Simon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08c7331b3eb8aee8c0dbe1402d40943e
Autor:
Joanita Ocen, Hendrik-Tobias Arkenau, Louise Carter, Mark Marion Kowalski, Elizabeth Ruth Plummer, T.R. Jeffry Evans, Manreet Randhawa, Sarah Danson, Debashis Sarker, Sarah P. Blagden, Robert H. Jones, Udai Banerji, Elena Cojocaru, Andrew Dye, Noor Md Haris, Rebecca Kristeleit, Ines Verdon, Stefan Symeonides, Harriet S. Walter
Publikováno v:
Journal of Clinical Oncology. 37:3094-3094
3094 Background: SRA737 is a potent, highly selective and orally-bioavailable inhibitor of checkpoint kinase 1 (Chk1). SRA737-01 was designed to investigate the safety and tolerability of continuous, daily dosing with SRA737 and to evaluate prelimina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c85b4e683480f90c6728ae46ddf161d4
https://doi.org/10.1200/jco.2019.37.15_suppl.3094
https://doi.org/10.1200/jco.2019.37.15_suppl.3094
Autor:
Daniel Giglio, Richard Cathomas, Gianfilippo Bertelli, Ian Beh, Jeff White, Helena M. Earl, Joanita Ocen, Martin Fehr, Scott Thomas Colville Shepherd, Paul D. Lewis, Susan Poole, Simon Tavaré, Patrick B. Mark, Edward H. Williams, Duncan I. Jodrell, Reed Stratton Geisler, Michael J. Dooley, Jamie M J Weaver, Amy Quinton, Tobias Janowitz
Publikováno v:
Journal of Clinical Oncology. 36:2565-2565
2565Background: Estimation of glomerular filtration rate (GFR) is essential for carboplatin chemotherapy dosing. However, the most accurate method to estimate GFR in patients with cancer is unknown...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd3efe25d4442c859446206a93e069a0
https://doi.org/10.1200/jco.2018.36.15_suppl.2565
https://doi.org/10.1200/jco.2018.36.15_suppl.2565
Publikováno v:
Journal of Clinical Oncology. 35:e17051-e17051
e17051 Background:Carboplatin based chemotherapy is widely used to treat women with Ovarian cancer (OC) in the adjuvant, neoadjuvant and palliative settings. Carboplatin is normally dosed by the Calvert formula: [GRF+25] x AUC, with a target AUC (are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9d886e922a35600d3ab5edbe8c20cbe
https://doi.org/10.1200/jco.2017.35.15_suppl.e17051
https://doi.org/10.1200/jco.2017.35.15_suppl.e17051